Browse By Person: Dong, Ying
|Up a level|
Group by: Item Type | Date
Number of items: 28.
Clements, Judith, Hooper, John, & Dong, Ying (2013) The human tissue kallikrein and kallikrein-related peptidase family. In Rawlings, Neil & Salvesen, Guy (Eds.) Handbook of Proteolytic Enzymes [3rd ed.]. Academic Press (Elsevier), New York & London, pp. 2747-2756.
Dong, Ying, Loessner, Daniela, Sieh, Shirly, Taubenberger, Anna V., Fuhrman-Luck, Ruth, Magdolen, V., et al. (2012) Cellular model systems to study the tumor biological role of kallikrein-related peptidases in ovarian and prostate cancer. In Schmitt, M., Magdoen, V., Somerhoff, C., & Fritz, H. (Eds.) Kallikrein-related peptidases [Volume 2] : Novel cancer-related biomarkers. deGruyter, Berlin, pp. 83-110.
Clements, Judith A., Hooper, John D., Odorico, Dimitri M., & Dong, Ying (2004) The Tissue Kallikrein Gene Cluster. In Barrett, Alan J., Rawlings, Neil D., & Woessner, J. Fred (Eds.) Handbook of Proteolytic Enzymes. Elsevier Academic Press, Netherlands, pp. 1569-1576.
Bui, Loan, Clements, Judith, Dong, Ying, Harvey, Tracey, Jarrott, Russell, & Walsh, Terence (2003) Production and Characterization of Antipeptide Kallikrein 4 Antibodies: Use of Computer Modeling to Design Peptides Specific to Kallikrein 4. In Russell, P, Jackson, P, & Kingsley, E (Eds.) Prostate Cancer Methods and Protocols. Humana Press, Totowa, New Jersey, USA, pp. 241-254.
Dong, Ying, Stephens, Carson, Walpole, Carina, Swedberg, Joakim, Boyle, Glen M., Parsons, Peter G., et al. (2013) Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLOS One, 8(2), e57056.
Dong, Ying, He, Yaowu, de Boer, Leonore, Stack, M. Sharon, Lumley, John W., Clements, Judith, et al. (2012) The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. The Journal of Biological Chemistry, 287(13), pp. 9792-9803.
Wilkinson, Ray, Woods, Katherine, D'Rozario, Rachael, Prue, Rebecca, Vari, Frank, Hardy, Melinda Y, et al. (2012) Human Kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunology Immunotherapy, 61(2), pp. 169-179.
Batra, Jyotsna, Nagle, Christina, O'Mara, Tracy, Higgins, Melanie, Dong, Ying, Tan, Olivia, et al. (2011) A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer, 11(119), pp. 1-11.
Dong, Ying, Lai, John, & Clements, Judith (2010) KLK7 (kallikrein-related peptidase 7). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 14(4), pp. 388-396.
Ricciardelli, Carmella, Bianco-Miotto, Tina, Jindal,, Dodd, Thomas, Cohen, Penelope, Marshall, Villis, et al. (2010) Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 19(7), pp. 1755-1765.
Zhao, Hong, Dong, Ying, Quan, Jingjing, Smith, Robert, Lam, Alfred, Weinstein, Stephen, et al. (2010) Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma. Head and Neck, 33(4), pp. 566-572.
Whitbread, Astrid, Veveris-Lowe, Tara, Dong, Ying, Tan, Olivia, Gardiner, Robert, Samaratunga, Hema, et al. (2010) Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry: official scientific journal of the GBM, 391(4), pp. 461-466.
Dong, Ying, Tan, Olivia, Loessner, Daniela, Stephens, Carson, Walpole, Carina, Boyle, Glen, et al. (2010) Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha 5 beta1 integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Research, 70(7), pp. 2624-2636.
Lai, John, Dong, Ying, & Clements, Judith (2009) KLK4 (kallikrein-related peptidase 4). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 13(12), pp. 944-949.
Ramsay, Andrew J., Reid, Janet C., Adams, Mark N., Samaratunga, Hemamali, Dong, Ying, Clements, Judith A., et al. (2008) Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological Chemistry, 389(6), pp. 653-668.
Ramsay, Andrew J., Dong, Ying, Hunt, Melanie L., Linn, MayLa, Samaratunga, Hemamali, Clements, Judith A., et al. (2008) Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. Journal of Biological Chemistry, 283(18), pp. 12293-12304.
Kaushal, Aneel, Myers, Stephen A., Dong, Ying, Lai, John, Tan, Olivia L., Bui, Loan T., et al. (2008) A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus. The Prostate, 68(4), pp. 381-399.
Dong, Ying, Matigian, Nick, Harvey, Tracey J., Samaratunga, Hemamali, Hooper, John D., & Clements, Judith A. (2008) Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biological Chemistry, 389(2), pp. 99-109.
Tan, Olivia, Whitbread, Astrid, Clements, Judith, & Dong, Ying (2006) Kallikrein-Related Peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers : do they have a function? Biological Chemistry, 387(6), pp. 697-705.
Dong, Ying, Bui, Loan, Odorico, Dimitri M., Tan, Olivia L., Meyers, Stephen A., Samaratunga, Hemamali, et al. (2005) Compartmentalized Expression of Kallikrein 4 (KLK4/hK4) Isoforms in Prostate Cancer: Nuclear, Cytoplasmic and Secreted Forms. Endocrine: Related Cancer, 12(Supp), pp. 875-889.
Clements, Judith, Hooper, John D., Dong, Ying, & Harvey, Tracey (2005) The Expanded Human Kallikrein (KLK) gene family : genomic organisation, tissue specific expression and potential functions. Biological Chemistry, 382(1), pp. 5-14.
Clements, Judith A., Willemsen, Nicole M., Myers, Stephen A., & Dong, Ying (2004) The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers. Critical Reviews in Clinical Laboratory Sciences, 41(3), 265 -312.
Dong, Ying, Kaushal, Aneel, Brattsand, Maria, Nicklin, Jim, & Clements, Judith A. (2003) Differential Splicing of KLK5 and KLK7 in Epithelial Ovarian Cancer Produces Novel Variants with Potential as Cancer Biomarkers. Clinical Cancer Research, 9, pp. 1710-1720.
Dong, Ying, Kaushal, Aneel, Chu, Simon, Bui, Loan T., Fuller, Peter J., Nicklin, Jim, et al. (2001) Human Kallikrein 4 (KLK4) Is Highly Expressed in Serous Ovarian Carcinomas. Clinical Cancer Research, 7(8), pp. 2363-2371.
Dong, Ying, Walsh, Michael D., Cummings, Margaret C., Wright, R. Gordon, Khoo, Soo Keat, Parsons, Peter G., et al. (1997) Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. The Journal of Pathology, 183(3), pp. 311-317.
Dong, Ying, Walsh, Michael D., McGuckin, Michael A., Gabrielli, Brian B., Cummings, Margaret C., Wright, R. Gordon, et al. (1997) Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. International Journal of Cancer, 74(1), pp. 57-63.
Dong, Ying, Berners-Price, Susan J., Thorburn, David R., Antatis, Toni, Dickinson, Joanne, Hurst, Terry, et al. (1997) Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines : targets for therapy. Biochemical Pharmacology, 53(11), pp. 1673-1682.
Dong, Ying, Berners-Price, Susan J., Thorburn, David R., Antatis, Toni, Dickinson, Joanne, Hurst, Terry, et al. (1997) Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy. Biochemical Pharmacology, 53(11), pp. 1673-1682.